Skip to content

Diagnostic Performance of Smart Supra Perimetry (The DPSSP Study)

Diagnostic Performance of Smart Supra Perimetry (SSP) in Comparison With Standard Automated Perimetry (SAP) and Ocular Coherence Tomography (OCT).

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03978546
Acronym
DPSSP
Enrollment
100
Registered
2019-06-07
Start date
2019-06-11
Completion date
2022-03-31
Last updated
2022-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Glaucoma, Suspect

Keywords

glaucoma

Brief summary

Early glaucomatous visual field changes can be missed with the routinely used Standard Automated Perimetry (SAP) and the 24-2 test pattern due to limited sampling of the central 10 degrees. While this shortcoming can be overcome with the addition of a 10-2 test, performing both tests places extra demand on the perimetric services (doubling test times) and patients. Smart Supra Perimetry (SSP) uses a new faster algorithm that can complete both 24-2 and 10-2 test patterns in a similar time frame to a single 24-2 SAP test. This comparative study aims to determine the sensitivity and specificity (i.e. diagnostic accuracy) of SSP in identifying early glaucomatous visual field loss. A sample of 100 patients with early/suspect glaucoma will undergo SAP 24-2 and 10-2 (SITA algorithm) using Humphrey visual field perimetry and SSP 24+10-2 using Henson 9000. Eyes will be categorised into 2 groups i.e., glaucoma and non-glaucoma, on the basis of structural changes to the disc as evaluated by the clinician. The sensitivity and specificity of the SAP and SSP tests will be established along with test duration. The size and location of defects established with both the SAP and SSP strategies will also be compared.

Interventions

DIAGNOSTIC_TESTHumphrey Visual Field Test

SITA Standard and 24-2 and 10-2 visual field tests

DIAGNOSTIC_TESTOptical Coherence Tomography (OCT) Scan

Circle and Wide Angle Scans

DIAGNOSTIC_TESTSmart Perimetry - Henson 9000

24+10-2 Smart Supra test

Sponsors

University of Manchester
CollaboratorOTHER
Columbia University
CollaboratorOTHER
Manchester University NHS Foundation Trust
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

All participants will have the same examinations but in a randomised order, these examinations are: Humphrey Visual Fields Test (10-2 and 24-2, SITA Standard), OCT Scan (Cube scan, Wide angle and macula scan) and Smart Perimetry - Henson 9000.

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Reliable SAP visual field results (fixation loss \< 33%, false positive \< 15% and false negative \< 20%). * Visual acuity better or equal to 0.20 logMAR. * Spherical refractive error within -6.00 to +6.00D and cylindrical error \<2.00D * No ocular co-morbidity likely to affect the visual field or OCT results. * Age: 40-80 yrs Additional inclusion criteria for glaucomatous group: * Optic disc showing glaucomatous changes. * SAP MD not worse than -6dB Additional inclusion criteria non-glaucoma group: * Normal SAP visual field data (MD, PSD, GHT within normal range) * No evidence of glaucoma or other Ocular co-morbidity in the eye suitable for the study.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic performance of smart supra perimetry12 monthsArea under the curve for Smart Suprathrold Perimetry using probability thresholds to differentiate early glaucoma from non-glaucomatous visual fields.

Secondary

MeasureTime frameDescription
Diagnostic performance of Optical Coherent Tomography12 monthsSensitivity and specificity for Optical Coherent Tomography in the detection of early glaucoma.
Diagnostic performance of Standard Automated perimetry12 monthsSensitivity and specificity for Standard Automated perimetry in the detection of early glaucoma.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026